RBC and Key Organics Announce Drug Discovery Collaboration
News Sep 05, 2005
Reaction Biology Corporation ("RBC") and Key Organics Ltd. have announced that they have created a Joint Venture ("JV") to engage in high throughput drug discovery.
The purpose of the JV is to identify a series of compounds with the potential of becoming drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets.
Key Organics supplies diverse sets of compounds synthesized in-house using classical organic procedures optimized for primary screening of druggable targets.
RBC's DiscoveryDot™ microarray technology is designed to reduce screening volumes to one nanoliter size, allowing large scale screening.
Key Organics will provide compounds for screening against these targets using RBC's DiscoveryDot™ screening technology.
Key Organics will then provide additional chemical analysis and compound synthesis, and RBC will perform additional screening and profiling. The companies will then collaborate on further development of selected compounds.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019